Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 146
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07917923 A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection… |
GT802 Injection | Myasthénie | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Daishi Tian | China · Tongji Hospital, Tongji Medical College, Huaz… | 2026-12 → 2031-12-30 | Ouvrir |
| NCT07673627 ADAPT Forward2 — ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safet… |
Empasiprubart IV | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | argenx | United States, Belgium, Greece, Japan, Netherlands, S… | 2026-07-10 → 2028-04 | Ouvrir |
| NCT06055959 ziMyG — A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Partic… |
Zilucoplan | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, Italy, Poland, South Korea, United Kin… | 2024-10-16 → 2027-06-22 | Ouvrir |
| NCT07217587 EPIC — Comparative Efficacy of Nipocalimab and Efgartigimod in Particip… |
Nipocalimab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Janssen Research & Development, L… | United States, Germany, Israel, Spain, Switzerland · … | 2026-01-05 → 2029-01-29 | Ouvrir |
| NCT07323316 HARMONY 360 — Holistic Assessment and Remote Digital MONitoring of mYas… |
MyoSense 360 | Myasthénie | Non applicable | RECRUITING | En attente / non publié | Ad scientiam | Denmark, France, Germany, Italy, Spain · Aarhus Unive… | 2026-10-06 → 2028-10 | Ouvrir |
| NCT07465289 MyVisionXT — A Study to Evaluate The Long-Term Safety And Efficacy of R… |
rozanolixizumab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, China, France, Georgia, Japan, Poland,… | 2026-09-16 → 2031-03-17 | Ouvrir |
| NCT07463521 MyVision — A Study to Evaluate the Efficacy and Safety of Rozanolixizum… |
rozanolixizumab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, Canada, China, France, Georgia, German… | 2026-05-27 → 2029-01-22 | Ouvrir |
| NCT07478172 Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults … |
Whole-body Electrical Muscle Stim… | Myasthénie | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | University of Missouri-Columbia | United States · NextGen Precision Health Building, Cl… | 2026-03-10 → 2031-01-07 | Ouvrir |
| NCT07246564 Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adul… |
rozanolixizumab | Myasthénie | Phase 4 | ACTIVE_NOT_RECRUITING | En attente / non publié | UCB Biopharma SRL | China · Mg0033 20040, Beijing, China | Mg0033 20172, … | 2025-12-01 → 2027-10-15 | Ouvrir |
| NCT06540144 An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizuma… |
rozanolixizumab | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | UCB Biopharma SRL | Italy, Japan, Poland, Turkey (Türkiye) · Mg0008 20081… | 2024-10-08 → 2027-10-05 | Ouvrir |
| NCT07647510 A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Mya… |
Claseprubart | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Dianthus Therapeutics | United States, Georgia, Ukraine · Cinical Study Site,… | 2026-06-29 → 2031-09 | Ouvrir |
| NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab … |
Ublituximab | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States · TG Therapeutics Investigational Trial… | 2026-11-01 → 2030-01-01 | Ouvrir |
| NCT07501702 ETNA — A Phase 2 Study to Evaluate Povetacicept in Adults With Generali… |
Povetacicept | Myasthénie | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Vertex Pharmaceuticals Incorporat… | United States, Australia, Poland, Turkey (Türkiye), U… | 2026-05-13 → 2029-03-02 | Ouvrir |
| NCT04833894 ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safet… |
Efgartigimod IV | Myasthénie | Phase 2/3 | ACTIVE_NOT_RECRUITING | En attente / non publié | argenx | United States, Austria, Belgium, Canada, France, Geor… | 2021-10-26 → 2027-03 | Ouvrir |
| NCT07304154 HERMOSA-2 — Study of KITE-363 in Participants With Autoimmune Neurologi… |
KITE-363 | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | Kite, A Gilead Company | United States, Australia, Canada · Centre Integre Uni… | 2026-04-10 → 2029-06 | Ouvrir |
| NCT06765161 Efgartigimod in IVIG Dependent Myasthenia Gravis Patients |
efgartigimod administration | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Clinique Neuro-Outaouais | Canada · Clinique Neuro-Outaouais, Gatineau, Canada | 2025-02-06 → 2027-01-06 | Ouvrir |
| NCT06626919 Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Pl… |
anito-cel | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | Kite, A Gilead Company | United States · Columbia University Irving Medical Ce… | 2025-04-30 → 2028-10 | Ouvrir |
| NCT07622342 A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Grav… |
SHR-2173 injection | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | Guangdong Hengrui Pharmaceutical … | China · Huashan Hospital, Fudan University, Shanghai,… | 2026-08-28 → 2027-12 | Ouvrir |
| NCT07596784 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With … |
Ravulizumab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Alexion Pharmaceuticals, Inc. | China · Research Site, Beijing, China | Research Site… | 2026-07-27 → 2027-08-24 | Ouvrir |
| NCT07022197 Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases |
BAFF-R CART | Myasthénie | Phase 1/2 | RECRUITING | En attente / non publié | Tianjin Medical University Genera… | China · Tianjin Medical University General Hospital, … | 2025-04-10 → 2027-12-30 | Ouvrir |
| NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gra… |
Telitacicept | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Vor Biopharma | United States, Argentina, Australia, Belgium, Brazil,… | 2024-07-17 → 2029-01 | Ouvrir |
| NCT06149559 roMyG — A Study of Rozanolixizumab in Pediatric Study Participants With… |
rozanolixizumab | Myasthénie | Phase 2/3 | COMPLETED | En attente / non publié | UCB Biopharma SRL | Italy, Japan, Poland, Turkey (Türkiye) · Mg0006 20339… | 2024-06-14 → 2026-10-05 | Ouvrir |
| NCT07583030 A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relaps… |
LVIVO-TaVec400 product | Myasthénie | Phase 1 | WITHDRAWN | En attente / non publié | Union Hospital, Tongji Medical Co… | China · Beijing Tiantan Hospital, Capital Medical Uni… | 2026-09-23 → 2026-09-23 | Ouvrir |
| NCT06987539 THYME — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Saf… |
Inebilizumab | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | Amgen | United States, Argentina, Brazil, France, Italy, Pola… | 2026-07-21 → 2030-03-13 | Ouvrir |
| NCT06744920 RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability … |
Remibrutinib (Blinded) | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Argentina, Australia, Brazil, Canada, … | 2025-02-07 → 2033-02-26 | Ouvrir |